KALA Pharmaceuticals, Inc. — Q1 2019 Form 10-Q
Entity note: The supplied filing identifies the registrant as Kala Pharmaceuticals, Inc. (Nasdaq: KALA), not “KALA BIO, Inc.” The quarter ended March 31, 2019; financial statements are unaudited.
Business context and reporting period
Kala is a biopharmaceutical company developing and commercializing eye-disease therapies using its AMPPLIFY mucus-penetrating particle technology. It launched INVELTYS in the United States in January 2019, its first commercial product. Its lead candidate, KPI-121 0.25%, is being developed for temporary relief of dry-eye signs and symptoms.
Financial results and position
| Metric | Q1 2019 | Q1 2018 / prior period |
|---|---|---|
| Net product revenue | $1.386 million | None |
| Cost of product revenue | $0.241 million | None |
| Gross profit / margin | $1.145 million / approximately 83% | Not applicable |
| Selling, general and administrative expense | $18.236 million | $5.482 million |
| Research and development expense | $6.959 million | $5.657 million |
| Operating loss | $24.050 million | $11.139 million |
| Interest expense / income | $2.094 million / $0.756 million | $0.367 million / $0.209 million |
| Net loss | $25.388 million | $11.297 million |
| Basic and diluted loss per share | $0.75 | $0.46 |
| Cash and cash equivalents at March 31 | $138.944 million | $170.898 million at Dec. 31, 2018 |
| Restricted cash at March 31 | $12.575 million | $12.206 million at Dec. 31, 2018 |
| Debt | $75.0 million principal; $70.457 million carrying value | $70.226 million carrying value at Dec. 31, 2018 |
Operating cash outflow was $31.170 million, versus $12.714 million in Q1 2018. Investing cash outflow was $0.444 million; financing provided $0.029 million. Cash and restricted cash declined $31.585 million during the quarter. Current assets were $150.449 million and current liabilities $14.602 million. Accumulated deficit was $226.497 million.
Material changes versus the prior comparable period
- Revenue began with INVELTYS’ January 2019 launch; reported net sales were $1.386 million.
- SG&A rose $12.754 million, principally due to sales-force and other hiring, launch marketing, and higher facilities costs. The company reported 57 territory sales managers, seven regional sales leaders and three national-account directors.
- R&D increased $1.302 million, mainly from KPI-121 STRIDE 3 development costs.
- Net loss increased $14.091 million. Interest expense increased $1.727 million, primarily reflecting the $75 million Athyrium borrowing outstanding throughout Q1 2019.
- Operating cash use more than doubled, reflecting the increased launch and development spending and working-capital needs, including receivables and inventory.
Outlook, commentary and risks
- The FDA’s target action date for KPI-121 0.25% was August 15, 2019. The company expected STRIDE 3 top-line results in Q4 2019. The filing gives no quantified sales or earnings guidance.
- Management expected significant operating losses and higher expenses to continue. It stated that March 31 cash would fund planned expenses, debt service and capital expenditures through at least mid-2020, with additional runway expected from INVELTYS revenue. The liquidity note separately says existing cash would fund those needs for at least twelve months from issuance of the statements.
- The Athyrium facility carries a 9.875% fixed rate, is secured by substantially all company assets, and includes a $10 million minimum-cash covenant. Interest-only payments run for four years; principal installments begin in 2022. An additional $35 million may be drawn if specified FDA-approval or INVELTYS-revenue conditions are met by June 30, 2020.
- Key risks include limited commercial-launch experience, uncertain market uptake and payer coverage, clinical and regulatory uncertainty for KPI-121, reliance on contract manufacturers, continuing cash burn, potential need for additional capital, and debt covenants and servicing costs. INVELTYS is the company’s only approved product and was approved only in the United States.
- The company reported no material legal proceedings and no material subsequent events. Disclosure controls were assessed as effective; launch-related revenue, inventory and cost controls were implemented and described as material changes to internal control over financial reporting.
Most important facts for investors to verify
- Confirm the registrant identity: the filing is for Kala Pharmaceuticals, Inc., despite the request metadata naming KALA BIO, Inc.
- Track INVELTYS prescriptions, net revenue, returns and rebate reserves, inventory, and payer coverage as launch data mature.
- Check KPI-121 regulatory status and STRIDE 3 results against the stated timeline; note the mixed prior Phase 3 results, including failure to meet STRIDE 2’s primary symptom endpoint.
- Reconcile the filing’s cash-runway statements: “at least mid-2020” in MD&A versus at least twelve months from financial-statement issuance in the liquidity note.
- Monitor cash burn, potential access to the conditional $35 million loan tranche, debt covenant compliance, and any financing or dilution needs.